Prediction of efficacy and viral kinetics using COBAS TaqMan HCV "automated" during antiviral treatment of hepatitis C

Toyota Joji, Karino Yosiyasu, Akaike Jun, Ohmura Takumi, Sato Takahiro, Yamazaki Katu, Kuwata Yasuaki, Arakawa Tomohiro, Furuya Shigeyuki, Matuyama Kazuhiro, Harada Takao

doi:10.2957/kanzo.49.297

Bibliographic Information

Other Title

コバスＴａｑＭａｎ　ＨＣＶ「オート」によるＣ型慢性肝炎抗ウイルス療法時のウイルス動態と効果予測
コバス TaqMan HCV オートニヨル Cガタマンセイカンエンコウウイルスリョウホウジノウイルスドウタイトコウカヨソク

Search this article

Description

Pretreatment and in-treatment viral kinetics as measured by Amp-M/Amp-Q and TaqMan were compared in 93 patients treated for chronic hepatitis C with peginterferon plus ribavirin combination therapy. In the association between pretreatment HCV RNA levels and virological efficacy, no clear fixed trend was observed by Amp-M whereas with TaqMan, a high SVR rate of 68.8% was observed in patients with 5- log RNA levels and a 40% non-response rate was observed in patients with high viral load (7- log and higher RNA levels). When the timing of HCV RNA negativity was compared by Amp-Q and TaqMan, a delay of 4 or more weeks was observed by TaqMan in over one-half of patients. The dissociation between the two test systems in the timing of negativity was particularly large in patients with slow viral attenuation. HCV dynamics in the early stage of treatment was also confirmed to be an important factor for predicting efficacy. Based on the above, TaqMan is more sensitive than Amp-Q and linearity is observed up through a higher viral region than Amp-M. TaqMan is therefore considered to be a superior method of measurement for HCV RNA monitoring in hepatitis C. <br>

Journal

Kanzo

Kanzo 49 (7), 297-306, 2008

The Japan Society of Hepatology

Keywords

Details 詳細情報について

Export

Report a problem